Vertex Pharmaceuticals Incorporated (VRTX)
NASDAQ: VRTX · Real-Time Price · USD
453.45
-3.24 (-0.71%)
Mar 9, 2026, 1:28 PM EDT - Market open
Vertex Pharmaceuticals Ratios and Metrics
Market cap in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 9, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Market Capitalization | 115,192 | 115,026 | 103,707 | 104,849 | 74,127 | 55,834 | Upgrade
|
| Market Cap Growth | -6.61% | 10.91% | -1.09% | 41.44% | 32.76% | -9.15% | Upgrade
|
| Enterprise Value | 105,730 | 104,851 | 94,253 | 91,965 | 65,181 | 49,750 | Upgrade
|
| Last Close Price | 456.69 | 453.36 | 402.70 | 406.89 | 288.78 | 219.60 | Upgrade
|
| PE Ratio | 29.65 | 29.10 | - | 28.97 | 22.31 | 23.84 | Upgrade
|
| Forward PE | 23.70 | 22.61 | 22.66 | 24.44 | 18.83 | 16.42 | Upgrade
|
| PS Ratio | 9.67 | 9.58 | 9.41 | 10.62 | 8.30 | 7.37 | Upgrade
|
| PB Ratio | 6.21 | 6.16 | 6.32 | 5.96 | 5.33 | 5.53 | Upgrade
|
| P/TBV Ratio | 6.76 | 6.71 | 7.15 | 6.70 | 6.07 | 6.42 | Upgrade
|
| P/FCF Ratio | 36.33 | 36.02 | - | 31.42 | 18.89 | 23.18 | Upgrade
|
| P/OCF Ratio | 31.95 | 31.68 | - | 29.64 | 17.95 | 21.12 | Upgrade
|
| PEG Ratio | 0.17 | 0.15 | 1.21 | 1.92 | 0.58 | 1.62 | Upgrade
|
| EV/Sales Ratio | 8.81 | 8.74 | 8.55 | 9.32 | 7.30 | 6.57 | Upgrade
|
| EV/EBITDA Ratio | 21.73 | 21.55 | 20.59 | 20.54 | 14.40 | 12.38 | Upgrade
|
| EV/EBIT Ratio | 22.56 | 22.37 | 21.45 | 21.35 | 14.89 | 12.78 | Upgrade
|
| EV/FCF Ratio | 33.10 | 32.83 | - | 27.56 | 16.61 | 20.66 | Upgrade
|
| Debt / Equity Ratio | 0.11 | 0.11 | 0.11 | 0.05 | 0.07 | 0.10 | Upgrade
|
| Debt / EBITDA Ratio | 0.40 | 0.40 | 0.37 | 0.18 | 0.20 | 0.24 | Upgrade
|
| Debt / FCF Ratio | 0.64 | 0.64 | - | 0.24 | 0.23 | 0.40 | Upgrade
|
| Net Debt / Equity Ratio | -0.55 | -0.55 | -0.58 | -0.73 | -0.72 | -0.65 | Upgrade
|
| Net Debt / EBITDA Ratio | -2.11 | -2.11 | -2.07 | -2.88 | -2.21 | -1.63 | Upgrade
|
| Net Debt / FCF Ratio | -3.22 | -3.22 | 11.99 | -3.87 | -2.54 | -2.72 | Upgrade
|
| Asset Turnover | 0.50 | 0.50 | 0.49 | 0.48 | 0.57 | 0.60 | Upgrade
|
| Inventory Turnover | 3.85 | 3.85 | 5.31 | 7.38 | 8.87 | 8.97 | Upgrade
|
| Quick Ratio | 2.24 | 2.24 | 2.17 | 3.60 | 4.46 | 4.04 | Upgrade
|
| Current Ratio | 2.90 | 2.90 | 2.69 | 3.99 | 4.83 | 4.46 | Upgrade
|
| Return on Equity (ROE) | 22.54% | 22.54% | -3.15% | 22.99% | 27.67% | 24.93% | Upgrade
|
| Return on Assets (ROA) | 12.16% | 12.16% | 12.14% | 13.17% | 17.33% | 19.32% | Upgrade
|
| Return on Invested Capital (ROIC) | 29.60% | 30.54% | -98.60% | 63.54% | 90.72% | 102.53% | Upgrade
|
| Return on Capital Employed (ROCE) | 21.50% | 21.50% | 23.20% | 22.50% | 28.40% | 34.50% | Upgrade
|
| Earnings Yield | 3.41% | 3.44% | -0.52% | 3.45% | 4.48% | 4.20% | Upgrade
|
| FCF Yield | 2.75% | 2.78% | -0.76% | 3.18% | 5.29% | 4.31% | Upgrade
|
| Buyback Yield / Dilution | -0.04% | -0.04% | 1.00% | -0.54% | 0.31% | 1.33% | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.